Cellectis-Cellartis Join Forces, Focus on Personalized Medicine
BioWorld Today Correspondent
LONDON – Cellectis SA today completes the acquisition of Europe's leading private stem cell company, the Swedish/British Cellartis AB, owner of 30 proprietary stem cell lines, in a cash and shares deal valued at €30 million (US$41.4million).
The deal will fuse Cellectis' expertise in the creation of induced pluripotent stem (iPS) cells from adult somatic cells with Cellartis' skills in differentiating embryonic pluripotent stem cells into specific cell types, including cardiomyocytes and hepatocytes.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST